These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28360139)

  • 21. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
    Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
    J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y
    Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
    Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
    Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.
    Shah N; Wang P; Wongvipat J; Karthaus WR; Abida W; Armenia J; Rockowitz S; Drier Y; Bernstein BE; Long HW; Freedman ML; Arora VK; Zheng D; Sawyers CL
    Elife; 2017 Sep; 6():. PubMed ID: 28891793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
    Wenjing H; Shao Y; Yu Y; Huang W; Feng G; Li J
    Prostate; 2020 Apr; 80(5):367-375. PubMed ID: 31967357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
    Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
    J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells.
    Tummala R; Lou W; Gao AC; Nadiminty N
    Mol Cancer Ther; 2017 Dec; 16(12):2770-2779. PubMed ID: 28729398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer.
    Li J; Alyamani M; Zhang A; Chang KH; Berk M; Li Z; Zhu Z; Petro M; Magi-Galluzzi C; Taplin ME; Garcia JA; Courtney K; Klein EA; Sharifi N
    Elife; 2017 Feb; 6():. PubMed ID: 28191869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
    Arora VK; Schenkein E; Murali R; Subudhi SK; Wongvipat J; Balbas MD; Shah N; Cai L; Efstathiou E; Logothetis C; Zheng D; Sawyers CL
    Cell; 2013 Dec; 155(6):1309-22. PubMed ID: 24315100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular determinants for enzalutamide-induced transcription in prostate cancer.
    Yuan F; Hankey W; Wu D; Wang H; Somarelli J; Armstrong AJ; Huang J; Chen Z; Wang Q
    Nucleic Acids Res; 2019 Nov; 47(19):10104-10114. PubMed ID: 31501863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.
    Gentile E; Hahn AW; Song JH; Hoang A; Shepherd PDA; Ramachandran S; Navone NM; Efstathiou E; Titus M; Corn PG; Lin SH; Logothetis CJ; Panaretakis T
    Cancer Res Commun; 2023 Dec; 3(12):2531-2543. PubMed ID: 37930121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.